Bayer reclaims cancer drugs in Lilly-Loxo buyout

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization of two cancer drugs.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news